What is the recommended dosing, contraindications, common adverse effects, and alternative anti‑anginal therapies for nicorandil in patients with chronic stable angina who cannot tolerate beta‑blockers, calcium‑channel blockers, or conventional nitrates?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Nicorandil for Chronic Stable Angina

Direct Recommendation

Nicorandil 20 mg twice daily is an appropriate third-line antianginal agent when beta-blockers, calcium-channel blockers, and conventional nitrates cannot be tolerated, though it carries only Class IIb (Level C) evidence and should not be combined with nitrates or used in patients with heart failure due to uncertain safety. 1, 2

Dosing

Standard dosing is 20 mg orally twice daily for angina prevention. 1

  • Start at a lower dose of 5 mg twice daily to minimize headache, then titrate upward over 1–2 weeks 2, 3
  • The usual therapeutic range is 10–20 mg twice daily 3, 4
  • For intravenous use in acute coronary syndromes, give a 2–14 mg bolus followed by continuous infusion titrated to clinical response 2
  • No nitrate-free interval is required, as tolerance develops less predictably than with conventional nitrates 1, 5

Place in Therapy

Nicorandil is positioned as a Class IIb recommendation (may be considered) when first-line agents fail or are contraindicated. 1, 2

Treatment Algorithm:

  1. First-line: Beta-1 selective blocker (bisoprolol 10 mg daily, metoprolol CR 200 mg daily, or atenolol 100 mg daily) 1, 6

  2. If beta-blocker intolerance or contraindication exists: Consider calcium-channel blocker (amlodipine preferred, Class IIa Level A), ivabradine (Class IIa Level A), long-acting nitrate (Class IIa Level A), or nicorandil (Class IIb Level C) 1, 2

  3. If beta-blocker monotherapy insufficient: Add dihydropyridine calcium-channel blocker 1

  4. If calcium-channel blocker combination fails: Substitute with long-acting nitrate or nicorandil 1

  5. Third-line add-on: Nicorandil may be added when two optimally dosed agents fail, though three-drug regimens may paradoxically provide less benefit than two 1, 6

The 2024 ESC guidelines downgraded nicorandil to Class IIb for add-on therapy due to limited high-quality evidence. 2

Contraindications

Absolute Contraindications:

  • Concomitant use with phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil)—Class I contraindication due to severe hypotension risk 2
  • Cardiogenic shock or severe hypotension 2
  • Active gastrointestinal ulceration (nicorandil can cause mucosal ulcers) 2

Relative Contraindications & Precautions:

  • Heart failure with reduced ejection fraction: Safety remains uncertain; use with extreme caution 2
  • Concomitant aspirin use: May increase risk of gastrointestinal ulcers, perforations, and hemorrhage 2
  • Do not combine with conventional nitrates: Lacks additional efficacy and increases adverse effects 2
  • Do not combine with ivabradine or ranolazine: Unknown safety profile 2

Common Adverse Effects

Headache is the most frequent adverse effect, occurring in approximately one-third of patients at therapeutic doses. 3, 4

  • Headache is typically mild-to-moderate, most frequent at treatment initiation, and declines with continued use 3
  • Approximately 5% of patients withdraw due to headache; starting at 5 mg twice daily reduces this rate 3
  • Other common effects: facial flushing, reflux, tachycardia, and hypotension 2, 5
  • Rare but serious: Skin, mucosal, and eye ulceration have been reported 2
  • Unlike conventional nitrates, nicorandil causes less orthostatic hypotension due to its balanced arterial and venous effects 5, 4

Alternative Antianginal Therapies

When beta-blockers, calcium-channel blockers, and nitrates cannot be tolerated, consider these alternatives in order of evidence strength:

Class IIa Recommendations (Should Be Considered):

  1. Ivabradine (sinus node inhibitor): 5–7.5 mg twice daily; reduces heart rate without negative inotropic effects (Level A evidence) 1, 2, 6

  2. Amlodipine (dihydropyridine calcium-channel blocker): 5–10 mg daily; safe in heart failure and does not affect AV conduction (Level A evidence) 2, 6

  3. Long-acting nitrates: Isosorbide mononitrate 30–60 mg once daily with a 10–12 hour nitrate-free interval to prevent tolerance (Level A evidence) 2, 6

Class IIb Recommendations (May Be Considered):

  1. Ranolazine: Metabolic agent that shifts metabolism from fatty acids to glucose; use as add-on or substitution therapy 1

  2. Trimetazidine: Another metabolic agent with anti-anginal efficacy 1

Special Populations:

  • Vasospastic (Prinzmetal) angina: Nicorandil 5 mg twice daily is third-line after calcium-channel blocker and long-acting nitrate fail 2
  • Coronary microvascular disease: Nicorandil 5 mg twice daily is third-line after beta-blocker and calcium-channel blocker 2

Clinical Outcomes & Evidence Quality

The IONA trial (5,126 patients) showed nicorandil reduced the composite endpoint of cardiovascular death, non-fatal MI, and unplanned hospitalization from 15.5% to 13.1% (HR 0.83,95% CI 0.72–0.97, p=0.014), driven primarily by reduction in unstable angina hospitalizations rather than mortality. 2

  • Nicorandil did not significantly reduce coronary heart disease mortality or non-fatal MI alone (5.2% vs 4.2%, HR 0.79,95% CI 0.61–1.02, p=0.068) 2
  • Short-term trials (median 5 weeks) show nicorandil is equivalent to beta-blockers, nitrates, and calcium antagonists for symptom control 7, 4
  • Comparative studies demonstrate sustained efficacy for up to 1 year without tolerance 3, 4
  • The TIBBS study showed bisoprolol was clearly more effective than nifedipine for anti-ischemic effects, reinforcing beta-blockers as first-line 1

Mechanism & Potential Cardioprotection

Nicorandil has a dual mechanism: potassium-channel activation (arterial vasodilation) plus a nitrate moiety (venodilation). 1, 3, 5

  • Reduces preload via venodilation and afterload via arterial dilation without impairing contractility or AV conduction 4
  • May exert direct cytoprotective effects through mitochondrial ischemic preconditioning 3, 5
  • Unlike pure nitrates, nicorandil maintains hemodynamic effects without requiring a drug-free interval 1, 5

Common Pitfalls & How to Avoid Them

  1. Starting at full dose: Begin at 5 mg twice daily to minimize headache, then titrate to 20 mg twice daily over 1–2 weeks 2, 3

  2. Combining with nitrates: This provides no additional benefit and increases adverse effects; substitute rather than add 2

  3. Using in heart failure: Safety is uncertain; avoid unless no alternatives exist 2

  4. Ignoring PDE-5 inhibitor use: Always screen for sildenafil, tadalafil, or vardenafil before prescribing—combination is absolutely contraindicated 2

  5. Expecting mortality benefit: Nicorandil reduces hospitalizations but has not proven mortality reduction; set realistic expectations 2

  6. Prescribing as first-line: Nicorandil is inferior to beta-blockers for both symptom control and prognostic benefit; reserve for intolerance or contraindication 1, 6

  7. Overlooking ulcer risk: Monitor for oral, anal, or skin ulcers, especially in patients on aspirin 2

References

2
Guideline

Nicorandil in the Treatment of Angina Pectoris

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

5
Research

Vasodilator Therapy: Nitrates and Nicorandil.

Cardiovascular drugs and therapy, 2016

6
Guideline

First‑Line Beta‑Blocker Therapy for Stable Angina with Irregular Rhythm

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the recommended dosing, contraindications, side effects, and monitoring for nicorandil tablets in an adult with chronic stable angina?
What is the recommended dosing, contraindications, and monitoring for Nicorandil in an adult with chronic stable angina inadequately controlled by beta‑blockers, calcium‑channel blockers, or long‑acting nitrates?
What is the pharmacology of nicorandil, its recommended dosing regimen, and the clinical conditions for which it is indicated?
What is the recommended intravenous nicorandil dosing, titration, and monitoring for an adult patient without severe hypotension who requires rapid vasodilation (e.g., refractory angina, acute coronary syndrome, or severe coronary vasospasm)?
What is the mechanism of action (MOA) of Nicorandil?
What initial dose of haloperidol should be started in a 59‑year‑old patient with vascular dementia who is severely agitated?
What is the recommended propylthiouracil (PTU) dosing regimen for an adult with thyrotoxicosis, including initial dose, maximum dose, thyroid storm dosing, maintenance dose, and considerations for first‑trimester pregnancy?
What does a serum immunoglobulin M (IgM) level of 31 mg/dL indicate in an adult and how should it be evaluated and managed?
How long should dapagliflozin (Farxiga) be held before a colonoscopy?
Can a patient with an iliac artery stent safely undergo chiropractic treatment, and what timing and safety considerations are required?
What cervical spine MRI protocol should be ordered for a patient with neck pain and ipsilateral arm numbness?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.